Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Biden outlines plan to quickly share 25 million COVID-19 vaccines with world

Published 03/06/2021, 21:18
Updated 03/06/2021, 22:55
© Reuters. FILE PHOTO: U.S. President Joe Biden delivers remarks on his administration's coronavirus disease (COVID-19) response, as Vice President Kamala Harris stands by in the Eisenhower Executive Office Building's South Court Auditorium at the White House in Was

(Refiles to change word in headline)

By Jeff Mason and Carl O'Donnell

WASHINGTON (Reuters) -The White House laid out a plan for the United States to share 25 million surplus COVID-19 vaccine doses to the world, with the first shots shipping as soon as Thursday, and said it would ease other countries' access to U.S.-made supplies for vaccine production.

President Joe Biden said the United States would give the vaccines without expectation of political favors in return. The dose shipments are the first of some 80 million COVID-19 vaccines that Biden has pledged to provide internationally this month as concern grows about the huge disparity in vaccination rates between advanced economies and developing countries.

The United States will donate nearly 19 million doses through the COVAX international vaccine-sharing program, Biden said in a statement. Through COVAX, some 6 million doses would go to Latin America and the Caribbean, about 7 million doses to South and Southeast Asia and roughly 5 million to Africa.

The remaining doses, amounting to just over 6 million, would go directly from the United States to countries including Canada, Mexico, India and South Korea, he said.

"We are sharing these doses not to secure favors or extract concessions," Biden said. "We are sharing these vaccines to save lives and to lead the world in bringing an end to the pandemic, with the power of our example and with our values."

Although the United States is working through COVAX co-run by the World Health Organization, the White House retains final say in which countries receive U.S. doses and how many, said national security adviser Jake Sullivan.

The White House will base donation decisions on "factors included achieving global coverage, responding to crises ... and helping as many countries as possible," Sullivan said, adding the United States intends to prioritize its neighbors, including Canada, Mexico and countries in Central and South America.

Reuters reported last month that the United States was considering prioritizing its own hemisphere, with Latin America a beneficiary.

The 25 million doses would be delivered quickly, with some going out as soon as Thursday, the White House said.

For months, the White House remained focused on getting Americans vaccinated as the coronavirus killed more than half a million people in the United States. But Biden promised the United States would become a supplier and send abroad at least 20 million doses of the Pfizer (NYSE:PFE) Inc/BioNTech SE, Moderna (NASDAQ:MRNA) Inc and Johnson & Johnson (NYSE:JNJ) vaccines, on top of some 60 million AstraZeneca (NASDAQ:AZN) Plc doses he had already planned to donate.

The 25 million doses Biden announced on Thursday will not include supply from AstraZeneca, the White House said.

International organizations including the United Nations and the World Bank welcomed the announcement. "It’s a good start, and I am hoping that more doses will be made available," World Bank President David Malpass said.

For Southeast Asian countries, it is a "symbolically important" first step, but the dose shipments are a "drop in the bucket" compared to what is needed in the region, said Alex Feldman, head of the U.S.-ASEAN Business Council, a lobbying group. He added that Indonesia, the Philippines, Vietnam and Thailand are facing serious difficulties with COVID-19.

LIFTING SOME RESTRICTIONS

The White House is also removing special powers it granted through the Defense Production Act (DPA) to certain vaccine makers that received U.S. funding but do not yet have U.S. approvals, including AstraZeneca, Sanofi (PA:SASY) SA/GlaxoSmithKline Plc, and Novavax Inc.

The DPA ratings give U.S. producers priority access to supplies and equipment needed to manufacture the vaccines that are in short supply around the world. Lifting them could free up raw materials for major vaccine makers elsewhere, especially the Serum Institute of India (SII).

Invoking the DPA helped the United States build a huge vaccine production system, while some companies overseas have struggled to get needed supplies to ramp up vaccine production.

SII, the world's largest vaccine maker and a top supplier of COVID-19 shots to low- and middle-income countries, had criticized the use of the DPA, and Reuters reported in May that a shortage of U.S.-made raw materials would hit production of Novavax's vaccine.

White House COVID-19 adviser Jeff Zients said the United States would continue to donate additional doses throughout the summer as more supply becomes available.

The International Monetary Fund and World Bank on Thursday urged the Group of Seven advanced economies to release any excess COVID-19 vaccines to developing countries as soon as possible, and called on manufacturers to ramp up production to benefit poor countries.

Pfizer has begun independently exporting millions of its U.S.-made shots largely to countries in Central and South America, Reuters reported last month.

© Reuters. FILE PHOTO: U.S. President Joe Biden delivers remarks on his administration's coronavirus disease (COVID-19) response, as Vice President Kamala Harris stands by in the Eisenhower Executive Office Building's South Court Auditorium at the White House in Washington, U.S., June 2, 2021. REUTERS/Carlos Barria/File Photo

Many Latin American countries have a dire need for vaccines as they combat outbreaks. Brazil has been one of the world’s hardest-hit countries by the pandemic, reporting more than 15 million cases and 400,000 deaths.

Peru this week revised its COVID-19 death toll, making it the country with the worst per-capita fatality rate.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.